This company has been marked as potentially delisted and may not be actively trading. XTL Biopharmaceuticals (XTLB) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsEarningsHeadlinesShort InterestTrendsBuy This Stock XTLB vs. RADX, KPTI, HSAQ, POCI, PYPD, AKTX, XLO, CLSD, MRM, and RMTIShould you be buying XTL Biopharmaceuticals stock or one of its competitors? The main competitors of XTL Biopharmaceuticals include Radiopharm Theranostics (RADX), Karyopharm Therapeutics (KPTI), Health Sciences Acquisitions Co. 2 (HSAQ), Precision Optics (POCI), PolyPid (PYPD), Akari Therapeutics (AKTX), Xilio Therapeutics (XLO), Clearside Biomedical (CLSD), MEDIROM Healthcare Technologies (MRM), and Rockwell Medical (RMTI). These companies are all part of the "medical" sector. XTL Biopharmaceuticals vs. Its Competitors Radiopharm Theranostics Karyopharm Therapeutics Health Sciences Acquisitions Co. 2 Precision Optics PolyPid Akari Therapeutics Xilio Therapeutics Clearside Biomedical MEDIROM Healthcare Technologies Rockwell Medical Radiopharm Theranostics (NASDAQ:RADX) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations. Do analysts recommend RADX or XTLB? Radiopharm Theranostics currently has a consensus target price of $15.00, suggesting a potential upside of 180.37%. Given Radiopharm Theranostics' stronger consensus rating and higher possible upside, analysts clearly believe Radiopharm Theranostics is more favorable than XTL Biopharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Radiopharm Theranostics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.67XTL Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is RADX or XTLB more profitable? Company Net Margins Return on Equity Return on Assets Radiopharm TheranosticsN/A N/A N/A XTL Biopharmaceuticals N/A N/A N/A Do institutionals & insiders have more ownership in RADX or XTLB? 4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. 29.0% of XTL Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has better earnings & valuation, RADX or XTLB? Radiopharm Theranostics has higher earnings, but lower revenue than XTL Biopharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRadiopharm TheranosticsN/AN/AN/AN/AN/AXTL Biopharmaceuticals$450K17.92-$1.03MN/AN/A Does the media refer more to RADX or XTLB? In the previous week, XTL Biopharmaceuticals had 2 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 2 mentions for XTL Biopharmaceuticals and 0 mentions for Radiopharm Theranostics. Radiopharm Theranostics' average media sentiment score of 0.12 beat XTL Biopharmaceuticals' score of 0.00 indicating that Radiopharm Theranostics is being referred to more favorably in the media. Company Overall Sentiment Radiopharm Theranostics Neutral XTL Biopharmaceuticals Neutral SummaryRadiopharm Theranostics beats XTL Biopharmaceuticals on 5 of the 9 factors compared between the two stocks. Get XTL Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XTLB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XTLB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XTLB vs. The Competition Export to ExcelMetricXTL BiopharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.57M$415.98M$5.53B$9.37BDividend YieldN/A2.45%4.74%4.12%P/E RatioN/A7.2128.8523.79Price / Sales17.923.36440.8796.30Price / CashN/A8.4135.0757.18Price / Book1.480.898.255.54Net Income-$1.03M$10.55M$3.25B$259.88M XTL Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XTLBXTL Biopharmaceuticals0.2315 of 5 stars$1.48+31.0%N/AN/A$7.57M$450K0.00N/AShort Interest ↑RADXRadiopharm TheranosticsN/A$4.78+0.6%$15.00+213.8%N/A$37.68M$1.68M0.00N/AGap DownKPTIKaryopharm Therapeutics3.423 of 5 stars$4.31-1.5%$37.40+768.8%-71.6%$37.20M$145.24M-0.32380Upcoming EarningsGap DownHSAQHealth Sciences Acquisitions Co. 2N/A$3.29+2.2%N/A-54.5%$36.89MN/A0.004Gap DownPOCIPrecision Optics0.2004 of 5 stars$4.78+1.6%N/A-23.8%$36.62M$19.10M-5.3780Positive NewsPYPDPolyPid2.2717 of 5 stars$3.52-3.2%$11.80+234.9%-6.6%$36.08MN/A-0.8280AKTXAkari Therapeutics2.6766 of 5 stars$1.10-3.1%$5.00+356.6%-73.1%$35.24MN/A0.009XLOXilio Therapeutics3.0217 of 5 stars$0.68-0.3%$4.00+488.2%-31.6%$35.21M$6.34M-0.8170News CoverageCLSDClearside Biomedical2.3839 of 5 stars$0.45+1.8%$4.20+827.2%-66.0%$35.13M$1.66M-1.1030Gap DownMRMMEDIROM Healthcare Technologies0.446 of 5 stars$1.24+2.0%N/A-61.7%$35.06M$8.30B0.00480Short Interest ↑RMTIRockwell Medical4.1508 of 5 stars$1.01-1.9%$4.00+296.0%-47.8%$34.51M$101.49M0.00300 Related Companies and Tools Related Companies Radiopharm Theranostics Competitors Karyopharm Therapeutics Competitors Health Sciences Acquisitions Co. 2 Competitors Precision Optics Competitors PolyPid Competitors Akari Therapeutics Competitors Xilio Therapeutics Competitors Clearside Biomedical Competitors MEDIROM Healthcare Technologies Competitors Rockwell Medical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XTLB) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredStrange twist to Bitcoin’s rallyThe #1 crypto to buy today Better than Bitcoin? (top crypto for less than $1) Over the past 15 years, B...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XTL Biopharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share XTL Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
